No Detail Found!

Preoperative denosumab and feasibility of less morbid surgery in campanacci stage 3 giant cell tumour of bone

Author(s)
Muhammad Asif Rasheed Combined Military Hospital, Rawalpindi, Pakistan.
Muhammad Suhail Amin Combined Military Hospital, Rawalpindi, Pakistan.
Muhammad Sohaib Nadeem Combined Military Hospital, Rawalpindi, Pakistan.
Muhammad Nadeem Chaudhry Combined Military Hospital, Rawalpindi, Pakistan.
Areej Fatima Combined Military Hospital, Rawalpindi, Pakistan.
Abstract
Background: Giant cell tumour of bone (GCTB) is a rare, locally aggressive benign bone tumour with slight female sex predilection and affecting young adults 20-40 years of age. World health organization (WHO) has recently categorized GCTB as an intermediate malignant tumour. GCTB is known to be driven pathologically via expression of pro-osteoclastic signals by stromal cells. This is mediated precisely via the expression of RANKL by stromal cells acting in an autocrine fashion on RANK receptor-positive osteoclast-like giant cells and their precursors. While the treatment is primarily surgical, we hypothesized that preoperative denosumab therapy facilitates conversion to a less morbid procedure in an aggressive campanacci grade 3 GCTB, otherwise amenable to joint resection and reconstruction/arthrodesis. Methods: A prospective, single arm, interventional study was conducted in Orthopaedics and radiation oncology department of combined military hospital (CMH) Rawalpindi. The duration of study was 36 months. Patients were recruited by purposive sampling technique as per inclusion/exclusion criteria. Denosumab was administered as preoperative adjuvant therapy for 3 months. Pain was assessed utilizing Brief Pain Inventory -Short Form (BPI-SF) and functional status was assessed as per Musculoskeletal tumour society score at baseline and 12 weeks after commencement of denosumab therapy. The intent of surgery pre and post denosumab therapy was ascertained. Results: Total of 23 patients were a part of this study. Mean pain scores and MSTS scores prior to and after denosumab were statistically significant with p-value <0.01. Pre-denusomab, there was inclination towards resection arthroplasty as the treatment procedure (56.5%). After denusomab therapy, intralesional curettage was choice of procedure with intent executed for 78.3% of cases. Conclusion: Denosumab has potential role for giant cell tumour of bone, it makes a less morbid surgery technically feasible. However, recurrence needs to be probed in long term follow up studies.
Publication Details
Page(s) 480-486
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
curettage, Denosumab, Giant cell tumour of bone
References
Patel S,Chiu RG,Rosinski CL,Ansari D,Chaker AN,Nunna RS .2020 .Outcomes of Spinal Giant Cell Tumour of Bone in Adult Patients: A National Cancer Database Analysis. World Neurosurg, 144 : e296-305.
Turcotte RE,Wunder JS,Isler MH,Bell RS,Schachar N,Masri BA .2002 .Giant cell tumour of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res, 397 : 248-58.
Choi JH,Ro JY .2021 .The 2020 WHO Classification of Tumours of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol, 28(1) : 44-58.
Thomas DM,Skubitz KM .2009 .Giant cell tumour of bone. Curr Opin Oncol, 21(4) : 338-44.
Forsyth RG,Krenács T,Athanasou N,Hogendoorn PCW,Cancers PCW .2021 .Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis. , 13(20) : 5119.
Peters S,Clézardin P,Márquez-Rodas I,Niepel D,Gedye C. .2019 .The RANK-RANKL axis: An opportunity for drug repurposing in cancer?. Clin Transl Oncol, 21(8) : 977-91.
Balke M,Hardes J .2010 .Denosumab: a breakthrough in treatment of giant-cell tumour of bone?. Lancet Oncol, 11(3) : 218-9.
Thomas D,Henshaw R,Skubitz K,Chawla S,Staddon A,Blay JY .2010 .Denosumab in patients with giant-cell tumour of bone: an openlabel, phase 2 study. Lancet Oncol, 11(3) : 275-80.
Atrayee BM,Chawla SP .2021 .. Giant Cell Tumour of Bone: An Update. Curr Oncol Rep, 23(5) : 51.
Girolami I,Mancini I,Simoni A,Baldi GG,Simi L,Campanacci D .2016 .Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol, 69(3) : 240-7.
Martin-Broto J,Cleeland CS,Glare PA,Engellau J,Skubitz KM,Blum RH .2014 .Effects of denosumab on pain and analgesic use in giant cell tumour of bone: interim results from a phase II study. Acta Oncol, 53(9) : 1173-9.
Rutkowski P,Ferrari S,Grimer RJ,Stalley PD,Dijkstra SPD,Pienkowski A .2015 .Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumour of bone. Ann Surg Oncol, 22(9) : 2860-8.
Serlin RC,Mendoza TR,Nakamura Y,Edwards KR .1995 .When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain, 61(2) : 277-84.
Guyatt GH,Osoba D,Wu AW,Wyrwich KW,Norman GR .2002 .Methods to explain the clinical signifi cance of health status measures. Mayo Clin Proc, 77(4) : 371-83.
Enneking WF,Dunham W,Gebhardt MC,Malawar M,Pritchard DJ M .1993 .A system for the functional evaluation of reconstructive procedures after surgical treatment of tumours of the musculoskeletal system. Clin Orthop Relat Res, : 241-6.
Traub F,Singh J,Dickson BC,Leung S,Mohankumar R,Blackstein ME .2016 .Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer, 59 : 1-12.
Campanacci M,Baldini N,Boriani S,Sudanese A .1987 .Giant-cell tumour of bone. J Bone Joint Surg Am, 69(1) : 106-14.
Amin MS,Chaudhary AA,Shah F .2017 .Management of Campanacci type III giant cell tumour. Int J Orthop Sci, 3(1) : 836-41.
Puri A,Gulia A,Hegde P,Verma V,Rekhi B .2019 .Neoadjuvant denosumab: Its role and results in operable cases of giant cell tumour of bone. Bone Joint J, : 170-7.
Yue J,Sun W,Li S. .2022 .Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumour of bone: A randomized clinical trial. J Bone Oncol, 35 : 100441.
Palmerini E,Pazzaglia L,Cevolani L,Pratelli L,Pierini M,Quattrini I .2022 .Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumours of Bone (GCTB): A Phase II Trial Correlative Study. Cancers, 14(12) : 2863.
Branstetter DG,Nelson SD,Manivel JC,Blay JY,Chawla S,Thomas D .2012 .Denosumab Induces Tumour Reduction and Bone Formation in Patients with Giant-Cell Tumour of Bone. Clin Cancer Res, 18 : 4415-24.
Lim CY,Liu X,He F,Liang H,Yang Y,Ji T .2020 .Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy. Bone Joint J, : 177-85.
Niu X,Yang Y,Wong KC,Huang Z,Ding Y .2019 .Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed. J Orthop Transl, 18 : 100-8.
Deventer N,Budny T,Gosheger G,Rachbauer A,Puetzler J,Theil JC .2022 .Giant cell tumour of bone: A single center study of 115 cases. J Bone Oncol, 33 : 100417.
Errani C,Tsukamoto S,Leone G,Righi A,Akahane M,Tanaka Y .2018 .Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumour of Bone Treated with Curettage. J Bone Joint Surg Am, 100(6) : 496-504.
Chinder PS,Hindiskere S,Doddarangappa S,Pal U .2019 .Evaluation of Local Recurrence in Giant-Cell Tumour of Bone Treated by Neoadjuvant Denosumab. Clin Orthop Surg, 11(3) : 352-60.
0

Citations

0

Downloads

79

Views